Ameripath Holdings Inc., a prominent player in the healthcare sector, is headquartered in the United States and operates extensively across various regions. Founded in 1999, the company has established itself as a leader in the anatomic pathology industry, providing high-quality diagnostic services and innovative solutions.
Ameripath is renowned for its comprehensive range of pathology services, including surgical pathology, cytopathology, and molecular diagnostics, which are distinguished by their accuracy and efficiency. The company’s commitment to leveraging advanced technology and expert pathologists has positioned it as a trusted partner for healthcare providers nationwide.
With a strong market presence and a reputation for excellence, Ameripath Holdings Inc. continues to achieve significant milestones, contributing to improved patient outcomes and advancing the field of pathology.
+21 vs industry average
Ameripath Holdings Inc.’s score of 43 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Ameripath Holdings Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Medical Laboratories has below-average carbon intensity
Industry performance
The Medical Laboratories industry has reduced its overall emissions by 28% since 2018
Reported emissions
No reported emissions data is available for Ameripath Holdings Inc. yet.
Ameripath Holdings Inc.'s reported carbon emissions
Ameripath Holdings Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Quest Diagnostics Incorporated, which may influence its climate-related initiatives and reporting.
While Ameripath Holdings Inc. has not established its own reduction targets or climate pledges, it is important to note that emissions data and performance metrics may be inherited from its parent company, Quest Diagnostics. This relationship suggests that any climate commitments or emissions reductions may align with those of Quest Diagnostics, which operates under its own sustainability framework.
As of now, Ameripath Holdings Inc. has not publicly committed to specific science-based targets or reduction initiatives. The lack of detailed emissions data highlights the need for transparency and accountability in corporate climate strategies, particularly in the healthcare sector, where operational impacts can significantly affect overall emissions profiles.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Ameripath Holdings Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Ameripath Holdings Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
Inherited from Quest Diagnostics Incorporated
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Ameripath Holdings Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project